"Isn't that like claiming a whole bottle of wine per day is good for your heart?"
No, not at all.
I'm dead serious.
Don't get me wrong though.
Note, I have split this article into two sections: a short summary and then the full deep dive. Let's start with the summary section.
Cannabinoids are compounds that stem from cannabis plants—such as hemp or marijuana. More than 100 different cannabinoids have been identified.
These cannabinoids are used to make cannabis-based products. Examples of such products are CBD oil for oral consumption or CBD wax which can be vaped.
Not all cannabinoids in existence have been thoroughly studied yet. In other words, many cannabinoids currently exist whose mechanisms in the human body are still unknown.
Science has some catching up to do.
I should mention, this article is rather lengthy. If you'd prefer to download a simple cheat-sheet guide, just enter your email below, and I'll send it to you.
The answer is simple.
That cannabinoid system has all kinds of functions. It helps with regulating your hormones, immune system, pain perception, and relaxation.
By ingesting CBD oil, you can massively affect all these health dimensions. It can help you relax, lower your pain, and improve pain perception.
CBD is not the only cannabinoid I'm addressing in this blog post though.
Both CBD and THC can actually play a role in improving your health through acting on the cannabinoid system in your body.
Yes, indeed. Even THC can yield positive health benefits.
I know that may sound counter-intuitive. Stay with me to find out more about THC.
Let me explain.
That's easy.
There's at least one downside to supplementing with cannabis-based products such as CBD oil.
Cannabis-based products are costly. For example, if you want to ingest the same dosages as those used in most clinical studies, CBD oil supplements would cost you $20–100 on a daily basis!
The list gets even better.
CBD oil may also help if you have a neurodegenerative disease, cancer, joint problems, psychological problems, epilepsy, or addiction.
In that case, I've got a few recommendations.
Make sure to buy high-quality, organically grown, full-spectrum CBD products.
Moreover, both of these companies use healthy oil to deliver their CBD products, are validated by third-party lab testing, and have full-spectrum CBD products.
The reason is simple.
Yes, THC is psychoactive.
But THC is also healing.
Cancer, chronic pain, eating disorders, and conditions with excessive inflammation all benefit from THC. Those inflammatory processes underlie many modern diseases, such as heart disease and diabetes.
Rather than simply rejecting THC across the board because it is very psychoactive, if it is needed for healing, I consider the psycho-activity of THC a fortunate (or unfortunate) side-effect. In other words, the use of THC is useful in certain health conditions despite its psychoactive effects.
An analogy is to consider that physicians are not denying morphine to suffering people just because it is psychoactive. It helps to understand that THC is another helpful resource for the management of chronic pain.
I conclude this blog post summary by claiming that it's best to optimize the cannabinoid system in your own body by developing healthy habits and only supplement if you already have a healthy lifestyle.
I consider two main cannabis plants in this blog post: hemp and marijuana—the heroes of this blog post's story.
Observe that these plants are hard to distinguish. Therefore, it's not surprising that the two plants have more similarities than just looks.
When you consume either of these plants, their cannabinoids affect the biology of your body. By affecting the biology of your body, cannabinoids influence your health. More than 100 different cannabinoids have been identified in nature. Most of these cannabinoids are contained in hemp and marijuana.[3]
Both the hemp and marijuana plants can be processed which results in cannabinoid-containing products and supplements which you can consume.
Don't worry.
Not at all...
I haven't created this blog post to prompt you to get you high. Instead, I'm considering what role cannabinoids can play in improving your health.
Let's, therefore, consider the two main cannabinoids of interest in this blog post:
Fortunately, you can immediately forget the difficult names. In this blog post, I'll just use their abbreviations, "CBD" and "THC".
Oh yes, there's one more thing.
The psychoactive effects of coffee and tea are subtle, just as with CBD oil.
The psychoactive effects of CBD's counterpart, THC, are more pronounced. THC is mainly found in the marijuana plant and is the reason people can get "high on weed."
Smoking is one of the most effective ways to absorb any compound thoroughly in your body. Thus, smoking marijuana is generally more effective than eating it if you want to get high.
But let's get back to THC.
To answer that question, we have to consider the differences between the cannabinoids in hemp and those in marijuana which are the two plants you just saw in the images above.
Speaking of THC...
Yes...
Is getting high a bad thing? Not necessarily...
"CBD Oil" derives its name from the cannabinoid CBD.
Let's assume you want CBD oil that contains a negligible amount of THC (<0.4%).
CBD oil can be extracted from most parts of the hemp plant including the leaves, stalks, and flowers. Most hemp-derived CBD oil contains about 0.3% THC. The rest of CBD oil is made up of 99.7% non-THC cannabinoids such as CBD.
While CBD oil can also be made from the non-THC parts of the marijuana plant, this option is less frequently chosen. Most people who want to completely avoid THC opt for hemp-based CBD oil. Hemp-based products come with greater assurance to be low in THC.
Before discussing the precise roles of CBD and THC, I do want to include a disclaimer: If you're not yet following a healthy lifestyle, you probably don't need to supplement with cannabinoids.
Yes...
You've read that right.
I know some readers might be getting tired of my sunlight recommendation in every blog post. And yet, I make this recommendation because I sincerely believe that nothing replaces the sun.
Sunlight is a free and essential tool that you can use to improve your health. However, people cannot make money off this recommendation. That's one of the reasons I think you will rarely hear about it.
It's not just the sun that improves how well your cannabinoid system functions. Physical exercise, for example, also affects your body's cannabinoid system.[6; 7; 8; 9; 10]
You should not rely on exercise to pursue the good feelings of cannabinoids because that strategy is unsustainable.
Well, most people in modern society are already too stressed. Exercise adds stress on top of stress.
If you choose to supplement with CBD or THC, there are thousands of different products on the market.
Let me simplify those offerings for you.
Both products can contain many other supporting cannabinoids (from among the 100 cannabinoids that have been identified so far).
These are the only two cannabinoid product categories I'm considering in this blog post. So you'll either end up with either a CBD-based product or a CBD+THC product.
When choosing a product, keep in mind one thing...
Most cannabinoid oil products also include an added oil (such as coconut oil) to increase absorption. You'll want to avoid cannabinoid products that contain vegetable oils as their carrier oil.
Well, fatty acids sourced from these plants massively decrease your health. Canola oil or sunflower oil probably increase your risk for heart disease, diabetes, and cancer. I cover this topic in more detail here → PUFAs: The Worst Thing For Your Health That You Eat Everyday
The previous habits I described to keep your body's cannabinoid system healthy are far more important.
In the US right now, the federal legal limit for THC is 0.3%. With some reservations, CBD oil can thus be considered "legal" (although the reality is complicated).
Some brands of hemp-based CBD oil nevertheless exceed that THC limit, which you have to take into account when buying CBD. For example, even though hemp is generally low in THC (<0.4% THC), sometimes growing conditions create hemp-based products that are higher in THC.
In the Netherlands - CBD oil is fully legal. THC is a more complex topic here. The same is true for many other EU countries.
There are exceptions: in the UK, even CBD oil products have a very complex and problematic legal status. In Australia or New Zealand, moreover, you're only allowed to buy CBD oil through a pharmacy or a physician.
There's no simple universal recommendation that I can make.
CBD oil can be legal today, and illegal tomorrow. Cannabis just does not experience world-wide acceptance in a way that another psychoactive substance such as alcohol or coffee does.
These legal issues are far too complicated to treat in this blog post: I would have to bore readers with the legalities in 150+ countries.
And I'm not doing that...
Why is clarifying the cannabinoid of specific countries so hard? Each country has different law regarding whether CBD and THC are:
Finally, we can now explore the health effect of cannabinoids.
The thousands of cannabis studies that have been carried out last decades, however, are new. This blog post explores cannabinoids from a scientific perspective.
My goal is not to report on what individuals say about what CBD oil or smoking weed brings to them...
In other words, I'm considering the health benefits of cannabis-based products that can be medically proven beyond a reasonable doubt.
In the future, cannabis-based products might turn out to have benefits that are not yet included in this blog post. That same future might also tell us that some benefits that I've ascribed to cannabis-based products are not as "rosy" as described in this blog post.
Future science will hopefully teach us more about cannabis, as the science on this topic is still developing.
Here we go again...
Throughout your body - and especially in your nervous system - which contain cannabinoid "receptors". Receptors are places in a cell that can receive chemical signals. Signalling substances in your body - called "neurotransmitters" - can bind to these receptors, which then start a chemical process.
Cannabinoids you consume affect these neurotransmitters.
In plain language, the cannabinoid system of your body can get "activated" through cannabinoids you consume.
Cannabinoids will thus influence your entire body instead of just your brain.
Your body's cannabinoid system regulates many biological processes, ranging from appetite to pain sensations, immune function, hormones, your energy levels, the activity of your nervous system, and your sleep quality.[56; 57; 197; 198; 199; 200; 201; 202]
For example, the system determines which hormones circulate in your body and their levels, or helps you to get in a good mood without anxiety before an important presentation.[22; 156; 157]
(Nerd section: It's not just CBD and THC that are affecting your body, but other cannabinoids such as cannabinol exhibit effects as well.[11; 24; 25] Other examples of cannabinoids are cannabicyclol, cannabicitran, and cannabifuran.[43; 295; 296; 297]
In reality, moreover, CBD oil does not directly influence the cannabinoid receptors, but through intermediaries that bind to the endo-cannabinoid receptors.[214; 215; 216] THC and CBD also bind to different cannabinoid receptors in your body, and in different manners--which is one reason why these two substances have such different effects.[100; 101] For readability purposes, I'm not outlining all the different receptors in your body.
Many receptors are targeted by CBD and other cannabinoids, such as the cannabinoid receptor 1, glutamate, GABA, glycine, 5-HT (serotonin) receptors, different transient receptor channel potential channels, PPAR-γ, GPR55, and adenosine.[52; 53; 54; 55; 102, 103] THC paints a different picture but the equally complex picture.)
In other words, how and why did your human body end up with a cannabinoid system of its own?
Millions of years...
The cannabinoid system is thus truly old. That system has developed over time through different types of species and plants.
The cannabinoid systems that could be found in animals 100 million years ago is thus not the same system as today.
The species that pre-dated humans and plants, have thus co-adapted for millions of years - together with their cannabinoid system. Even though cannabinoids are hundreds of millions years old, they have not changed that much over time.[365]
In a sense, cannabinoids are a common ancestor that still connect humans and the plant world.
The biological activity that cannabis products have on your health is thus not accidental, but completely expected.
Let's take a look at CBD (oil), the most important cannabis-based product that has become popular in the last decade.
First: CBD.
While I'm talking about CBD oil in this section, you can just as easily replace the oil with other CBD based products - such as CBD e-liquid for vaping. Different methods of consuming CBD products are treated in another section as well.
You thus need CBD to get the benefits listed below.
In addition to overall health benefits, CBD oil is often used by people who have diseases. Let's look at where the use of CBD oil has proven validity.
The picture I'm giving you of CBD almost seems too good to be true.
So, as a conclusion, CBD oil can fix your anxiety and help cure cancer...
That depends...
In the next section, the CBD story turns somewhat sour. That section considers the delivery methods and dosages of CBD oil. It turns out that achieving the exact same dosages as the studies I'm quoting is expensive.
By the way, want a simpler 10-step infographic that tells you all you need to know about cannabis-based products, such as CBD and THC. Grab that infographic here:
Before diving into different CBD consumption methods, let's look at how CBD dosages are expressed.
There are many different methods to get these milligrams of CBD into your body.
Alternatively, you can let the oil absorb under your tongue. Next, there are CBD wax and e-liquid products, which are used for vaping. Then there are CBD-based products that can be smoked, or products that can be mixed through food.
I'll treat the best CBD consumption methods one-by-one so that you always get the most out of a product
First, there's the oral route - ingesting CBD oil and simply letting it absorb through your stomach.
In many scientific studies, participants simply ingest the CBD oil orally, as they would ingest a pill. Let's look at doses used in these studies:
Just one full bottle of CBD oil often contain anywhere between 100-1000mg of CBD. And these bottles are costly.
That's correct.
$70 per day...
If you use 300mg per day for anxiety purposes, a 600mg bottle will last you only through 2 episodes. That's $35 per episode. For treating epilepsy, the 600mg bottle will not even last one day: you might need 800mg.
Not necessarily.
Many people report having great results with taking CBD oil orally on dosages that are much lower than the 200-800mg used in scientific studies.
Many people do well on 10-40mg CBD oil each day. I have used such dosages when I'm testing CBD oil products, and the effects are very noticeable.
Remember that my article is concerned with what effects cannabis can have for your health based on current scientific research.
Low doses of CBD taken orally have not been studied extensively. From anecdotal evidence, however, because thousands if not millions of people use CBD-based products, you can reasonably assume that CBD does work at lower dosages.
If you begin with a dose that's too high, CBD oil might counteract the goal you're trying to accomplish. Let's, for example, say you take CBD oil for anxiety issues. In that case, a high dose of CBD oil will increase your anxiety rather than decreasing it.[69: 70; 71]
I recommend everyone start with a low dose of 10mg, and see whether they feel anything. If you don't feel anything, up the dose to 20mg the week. If you do not feel anything at that point, increase the dose to 40mg the week afterwards.
If you need results quickly, you can opt to increase the dose every few days.
A 70kg person would thus use a dosage of 700mg CBD oil as their maximum dosage - presupposing they take CBD orally.
Don't be scared of overdosing with CBD oil via the oral route, as long as you build up your dosage gradually.
Overdoses on CBD are thus almost impossible...
I only show you these high dosages to demonstrate that my 10mg per kilogram of bodyweight maximum dose is very safe and conservative. Only commit to higher than my proposed 10mg per kg dosage after consulting with your physician though.
(Nerd section: in animal studies, doses of 20 - 120 mg per kg of body weight are used without any dangerous side effects.[85, 118; 119; 123; 124; 129] That's many times the maximum dosage used in humans.)
There's some truth to that...
Perhaps not...
Vaping is another great delivery method of CBD consumption:.
Vaping pure CBD does lead to much higher levels reaching your bloodstream than just swallowing the compound.[258] While there's no absolute certainty at this point, vaping can be up to 6 times as effective as ingesting CBD oil orally.
Yes, that number is shocking...
Now you're in money-saving territory.
The big difference between vaping CBD and taking CBD oil under the tongue is how quickly the substance is acting:
With a vaporizer device, you can heat a substance that is then turned into a gas, which you inhale into your lungs. Remember that the lungs are one of the most effective ways to get substances absorbed into your body. Substances that enter the lungs can directly enter your bloodstream.
Vaping might also fundamentally alter your cannabis-consuming experience. Vaping allows substances to pass to your brain that are otherwise not absorbed if you take CBD orally.
Perhaps...
Vaping exposes your body to additional substances, such as "propylene glycol" or "glycerine". Some people do not respond favorably to these substances.
Overall, nonetheless, the ability to vape CBD seems very promising.
Yes...
Cannabinoids stay in your body much longer when you ingest them orally. Even though fewer cannabinoids are absorbed through the oral route, you don't have to dose CBD very often orally.[360; 361]
In some instances, less frequent dosing can be beneficial. If you cannot vape 5-10 times each day at work, oral CBD might be the (expensive) solution.
There's thus no clear all-round winner in regarding cannabinoid supplements, that is best in each and every circumstance.
Dosing cannabinoids is complicated. The doses I've given for specific diseases or illnesses are not set in stone. All doses are a rough guideline.
Remember the example of different people smoking CBD-based products in different ways. Smoking techniques influenced CBD absorption levels.
The full story is even more complex than that.
You see, all people also have different weights, different liver functions, different tolerance levels to cannabinoids, different genetics, etcetera.
Let me illustrate that point with an extreme example. One person, a woman, might be 20 years old, athletically fit, and weighing 55 kilograms. The second person might be a man, 40 kilograms overweight, 60 years old, having liver problems, and on 3 different types of prescription medication.
Again: always build your cannabis-based product dosage up slowly.
And just as important: always lower your cannabis-based product dosage slowly as well. Both upping and lowering the cannabinoid dosage thus takes time. If you quit cannabis-based products "cold turkey", you'll probably experience side effects from the withdrawal.
That list should help you make a good choice and you can see why I have settled with CDBPure.com to be my go-to (and recommended) CBD source (use discount code ALEX to save 10% on CBDPure products).
Next, let's look at how to avoid having cannabinoids interact with your prescription medicine.
Not everyone can just take CBD-based products. If you don't take any prescription drugs for your health, skip this section.
Prescription drugs you take might influence how CBD-based products functions in your body--and CBD-based products might also affect how prescription drugs are processed in your body.
Hormones, antibiotics, drugs for your heart, anti-acids for the stomach, different types of painkillers, diabetes medication, and drugs of the gastrointestinal system.
(Nerd section: Here I'll venture into some specific prescription drugs that are affected by CBD. Certain drugs that counteract yeast (ketoconazol; itraconazol), HIV or AIDS (ritonavir), bacterial infections (clarithromycin), promote higher blood levels of CBD oil.[82]
Alternatively, some drugs will decrease how fast the blood levels of CBD oil rise, clearing the product faster from your body. Examples are epilepsy drugs (phenobarbital; carbamazepine; levetiracetam; felbamate; valproic acid; phenytoin), and different anti-bacterial infection drugs (rifampicin).
Hexobarbital, a hypnotic drug that makes you relaxed, is also influenced by cannabinoids consumption.[115; 116] Another anti-epileptic sedative (or - benzo), clobazam, is also affected.[135] Antispychotics are also affected, such as risperidone.[117]
Paracetamol and antipsychotic drugs (specifically haloperidol) are not affected by CBD oil consumption.[82]
Lastly, cannabinoids might alter how certain drugs are metabolized through the cytochrome P450 system.[269; 270; 271] This system might affect several drugs--although many of these interactions have not yet been investigated specifically. Examples of such drugs are antihistamines, hormonal drugs, antibiotics, beta blockers or anti-arrhythmic drugs, epilepsy medicine, anti-acids for the stomach, calcium channel blockers, drugs affecting the proton pump, statins, beta-blockers, etcetera.)
Simply put: almost any prescription medication can be influenced by CBD-based products - even THC.
I want to re-emphasize a point I made earlier: THC-based compounds are illegal in many countries. I nevertheless discuss these compounds here, in the hypothetical situation that anyone might try them anyway.
I'm thus not recommending the use of THC, but just looking at which effects THC have on your health.
THC is the main active compound in marijuana based weed - that many people smoke. What effects will THC have on you in higher doses?
That's not the route I'm going to take here.
The main purpose of ingesting THC in that instance is not to get high - it's curative. Becoming "high" will just be a byproduct of the medical use of THC.
I don't think your judgment of the psychoactive effects of THC needs to cloud the judgment of THC's possible healing effects. I must admit - I had an "anti-psychoactive bias" before writing this blog post as well, assuming that only CBD could have had positive health effects because CBD is less psychoactive.
I was wrong.
(Nerd section: This section does not only treat what is commonly understood as "THC". THCs can actually be subdivided into several compounds, such as "d-8-THC" and "d-9-THC", and "d-11-THC". "Regular THC" denotes the d-9-THC substance.
Marijuana research mainly focuses on d-9-THC, but d-11-THC might be even more interesting - being able to achieve quadruple therapeutic effects of d-9-THC.
The interactions between CBD and THC are extremely interesting. In some areas, the effects of THC and CBD counter each other, such as THC's possible side-effects.[27; 32; 151] In some other studies, however, CBD increases the effects of THC.[11; 26] Cannabinoids essentially work synergistically, which is why full-spectrum cannabis products are recommended in this blog post.[297])
The results are an imbalance...
These drugs do therefore not contain the higher levels of CBD to cancel some of the negative effects of THC.[28; 98; 99] For example, the ingestion of compounds with a higher THC to CBD ratio is associated with greater anxiety and depression levels.[31; 35; 36; 37; 38; 60]
At most, the THC and CBD dose should be roughly equal.
My overall advice is to be careful.
While it's not established that ingesting cannabis products that are mainly based on THC causes you to be anxious or depressed, more people who are anxious and depressed do seem to be using such products. In other words, weed may be a way of dealing with anxiety or depression.
Yes.
Smoking weed - thus using mostly THC - also increases the chance you getting a psychotic illness.[40; 41; 42] Schizophrenia is an example of such a psychotic illness. Keep in mind that some people are far more vulnerable to the negative effects of THC than others.[174]
Any time CBD with THC are combined, the side effects of cannabis also increase, compared to taking just using CBD.[151]
Euphoria is often cited as a side-effect as well--but can only be considered a side effect if you're biased against the psychoactive effects of drugs. I do not consider euphoria a side effect unless you consider the "high" from THC inherently unpleasant.
But let's look at the bright side.
If you use a full-spectrum cannabinoid product, moreover, the psychoactive effects of THC might be decreased as well.[12; 344]
CBD lowers the psychoactive effects of THC.
THC can make you feel great in the short term, but there is a long-term price to pay. In the long-run, for example, THC lowers the amount of deep sleep and dreams you experience, makes it harder to fall asleep and makes you sleep fewer hours.[112; 176; 177]
For me, THC's effects on sleep make the substance already worthless if you're healthy.
THC can cause (negative) hormonal disruption, such as increasing the estrogen hormone.[256; 257] Most people in modern societies already estrogen levels that are too high.
Many of the side-effects are reduced or absent when you combine THC with CBD. Moreover, THC can even increase the effects of CBD.[12; 298]
I do think the interaction between THC and CBD make a very strong case for always choosing a full-spectrum cannabis product that always contains CBD, whether or not that product contains THC.
Just be aware of the price you're paying when using THC based products that are low in CBD and other cannabinoids. High THC products in the absence of CBD are somewhat unnatural, and may come with side-effects.
You've previously learned about the very important cannabinoid system of your body.
Post-Traumatic Stress Disorder, ADD, autoimmune diseases such as MS, psychiatric illnesses, depression, anxiety, and addiction.[157; 189; 190; 191; 192; 193; 194; 203] The careful reader will notice that many of these conditions are also treated by ingestion of cannabinoids, such as CBD oil.
Besides disease, there are other reasons why your body's cannabinoid system matters. For example, the cannabinoid system regulates how your body deals with rewards and anxiety.
Remember that your body's cannabinoid system regulates everything from your hunger, energy levels, immune system, pain perception, libido, to sleep quality.[197; 198; 199; 200; 201; 202]
I previously advised using sunlight and exercise (if non-stressed) to improve how well your body's cannabinoid system functions.[6; 7; 8; 9; 10; 182] I also promised to give you additional strategies to optimize the cannabinoid system in your body.
There you have it. Several strategies to keep the cannabinoid system of your body healthy.
THC and CBD - the full spectrum product - is what nature meant cannabis products to be.
(Nerd section: there are many other methods that can be used to increase the endocannabinoid system in your body. Examples are supplements such as Palmitoylethanolamide (PEA), magnolia extract, the use of hormones such as cortisol and or adrenaline, drugs such as aspirin, benzos, or morphine, I do not consider these useful nor viable strategies for those who are attempting to improve their health.[205])
A full 600mg bottle of CBD oil will last you 2 days, if you use the scientifically validated dose of CBD oil for decreasing anxiety during a presentation.
Buy alternatives...
Then lastly, there's another possibility: grow your own cannabis plants.
Make sure it's legal before you decide to produce your own cannabis plants. Nevertheless, you can find many guides online on how to select specific cannabis strands.
Creating your own cannabis plants is a much cheaper alternative than buying this stuff online. I don't have any experience with this option though, so I'm not the best guide in this specific process!
All you need to know about cannabis-based products, such as CBD and THC...
Want an infographic that summarized this blog post with the 10 key points I got from looking at hundreds of studies on cannabis? Grab that infographic below:
There are instances in which cannabinoids can be extremely helpful. Cancer and epilepsy come to mind.
In many other instances, there are many (much less expensive) alternatives that I would suggest trying first, before spending their preciously earned money on CBD oil - or THC.
Also, remember that my guide on CBD and THC mostly focuses on the benefits of cannabis-based products that can be proven beyond a reasonable doubt.
Lots of users of cannabis on the internet report receiving absolutely spectacular benefits from cannabis-based products.
On the one hand, I'm sceptical towards claiming that cannabis can cure almost any illness. On the other hand, scientific studies will hopefully validate amazing benefits in the future - proving me wrong.
Also, keep in mind that cannabinoids have a 600-million-year history that precedes all plants and human beings.
It's thus expected that many new cannabis effects will be found. I'm thus assuming that this science-focused guide will look very different if it is rewritten in 2025!
[1] Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid signalling: has it got rhythm? Br J Pharmacol. 2010 Jun;160(3):530-43. doi: 10.1111/j.1476-5381.2010.00790.x.
[2] Zheng D, Bode AM, Zhao Q, Cho YY, Zhu F, Ma WY, Dong Z. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res. 2008 May 15;68(10):3992-8. doi: 10.1158/0008-5472.CAN-07-6594.
[3] Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A. Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. J Nat Prod. 2016 Feb 26;79(2):324-31. doi: 10.1021/acs.jnatprod.5b00949. Epub 2016 Feb 2.
[4] Harrington CR, Beswick TC, Leitenberger J, Minhajuddin A, Jacobe HT, Adinoff B. Addictive-like behaviours to ultraviolet light among frequent indoor tanners. Clin Exp Dermatol. 2011 Jan;36(1):33-8. doi: 10.1111/j.1365-2230.2010.03882.x.
[5] Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012 Jul;109(29-30):495-501. Epub 2012 Jul 23.
[6] Tantimonaco M, Ceci R, Sabatini S, Catani MV, Rossi A, Gasperi V, Maccarrone M. Physical activity and the endocannabinoid system: an overview. Cell Mol Life Sci. 2014 Jul;71(14):2681-98. doi: 10.1007/s00018-014-1575-6. Epub 2014 Feb 14.
[7] Dietrich A, McDaniel WF. Endocannabinoids and exercise. Br J Sports Med. 2004 Oct;38(5):536-41.
[8] Brellenthin AG, Crombie KM, Hillard CJ, Koltyn KF. Endocannabinoid and Mood Responses to Exercise in Adults with Varying Activity Levels. Med Sci Sports Exerc. 2017 Aug;49(8):1688-1696. doi: 10.1249/MSS.0000000000001276.
[9] Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. 2016 Jan;41(1):80-102. doi: 10.1038/npp.2015.166. Epub 2015 Jun 12.
[10] Raichlen DA, Foster AD, Seillier A, Giuffrida A, Gerdeman GL. Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol. 2013 Apr;113(4):869-75. doi: 10.1007/s00421-012-2495-5. Epub 2012 Sep 19.
[11] Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012 Dec;2(6):241-54. doi: 10.1177/2045125312457586.
[12] Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344-64. doi: 10.1111/j.1476-5381.2011.01238.x.
[13] Li H. An archaeological and historical account of cannabis in China. Economic Botany 1973 28: 437–448
[14] Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). 2006 Apr;30 Suppl 1:S13-8.
[15] Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008 May;20 Suppl 1:10-4. doi: 10.1111/j.1365-2826.2008.01671.x.
[16] Izzo AA. Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol. 2004 Aug;142(8):1201-2. Epub 2004 Jul 26.
[17] Kendall DA, Yudowski GA. Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Front Cell Neurosci. 2017 Jan 4;10:294. doi: 10.3389/fncel.2016.00294. eCollection 2016.
[18] Oleson EB, Cheer JF. A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a012229. doi: 10.1101/cshperspect.a012229.
[19] Szabo B, Müller T, Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem. 1999 Sep;73(3):1084-9.
[20] Pickel VM, Chan J, Kearn CS, Mackie K. Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol. 2006 Mar 20;495(3):299-313.
[21] García C, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol. 2016 Jul;173(13):2069-79. doi: 10.1111/bph.13215. Epub 2015 Jul 31.
[22] Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006 Feb;27(1):73-100. Epub 2005 Nov 23.
[24] Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129-80.
[25] Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008 Jan;153(2):199-215. Epub 2007 Sep 10.
[26] Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res. 2008 Jan 10;1188:157-64. Epub 2007 Oct 12.
[27] Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol. 1974 Sep;28(1):172-7.
[28] Niesink RJ, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130.
[29] Colizzi M, Bhattacharyya S. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. Curr Addict Rep. 2017;4(2):62-74. doi: 10.1007/s40429-017-0142-2. Epub 2017 Apr 29.
[30] Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, Seal ML, Martin-Santos R, Ffytche D, Zuardi AW, Atakan Z, McGuire PK. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology. 2011 Jun;36(7):1340-8. doi: 10.1038/npp.2011.17. Epub 2011 Mar 16.
[31] Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, Zuardi AW, McGuire PK. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009 Jan;66(1):95-105. doi: 10.1001/archgenpsychiatry.2008.519
[32] Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, Mechelli A, Atakan Z, McGuire P. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009 Apr;66(4):442-51. doi: 10.1001/archgenpsychiatry.2009.17.
[33] ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol Psychiatry. 2016 Apr 1;79(7):613-9. doi: 10.1016/j.biopsych.2016.01.004. Epub 2016 Jan 19.
[34] Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. 2012 Mar;5(1):32-40.
[35] Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, Curran HV. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. 2012 Feb;42(2):391-400. doi: 10.1017/S0033291711001322. Epub 2011 Jul 29.
[36] Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry. 2014 May 10;14:136. doi: 10.1186/1471-244X-14-136.
[37] Troup LJ, Andrzejewski JA, Braunwalder JT, Torrence RD. The relationship between cannabis use and measures of anxiety and depression in a sample of college campus cannabis users and non-users post state legalization in Colorado. PeerJ. 2016 Dec 8;4:e2782. eCollection 2016.
[38] Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017 Nov;34(11):1006-1017. doi: 10.1002/da.22664. Epub 2017 Jun 21.
[39] Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1.
[40] Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007 Jul 28;370(9584):319-28.
[41] DamjanoviÄ A, PantoviÄ M, DamjanoviÄ A, DunjiÄ-KostiÄ B, IvkoviÄ M, MilovanoviÄ S, LackoviÄ M, DimitrijeviÄ I. Cannabis and psychosis revisited. Psychiatr Danub. 2015 Mar;27(1):97-100.
[42] Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry. 2014 May 22;5:54. doi: 10.3389/fpsyt.2014.00054. eCollection 2014.
[43] Radwan MM, Ross SA, Slade D, Ahmed SA, Zulfiqar F, Elsohly MA. Isolation and characterization of new Cannabis constituents from a high potency variety. Planta Med. 2008 Feb;74(3):267-72. doi: 10.1055/s-2008-1034311. Epub 2008 Feb 18.
[44] Maida V, Daeninck PJ. A user's guide to cannabinoid therapies in oncology. Curr Oncol. 2016 Dec;23(6):398-406. doi: 10.3747/co.23.3487. Epub 2016 Dec 21.
[45] Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50-2. Epub 2005 Nov 9.
[46] Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389.
[47] Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10.
[48] de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Crippa JA, Zuardi AW, Nardi AE, Silva AC. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953-60.
[49] Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther. 2013 Apr;138(1):18-37. doi: 10.1016/j.pharmthera.2012.12.002. Epub 2012 Dec 20.
[50] Marco EM, García-Gutiérrez MS, Bermúdez-Silva FJ, Moreira FA, Guimarães F, Manzanares J, Viveros MP. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci. 2011 Oct 5;5:63. doi: 10.3389/fnbeh.2011.00063. eCollection 2011.
[51] Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22.
[52] Franklin JM, Carrasco GA. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse. 2013 Mar;67(3):145-59. doi: 10.1002/syn.21626. Epub 2012 Dec 8.
[53] O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016 Jun;173(12):1899-910. doi: 10.1111/bph.13497. Epub 2016 May 19.
[54] Xiong W1, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang L. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med. 2012 Jun 4;209(6):1121-34. doi: 10.1084/jem.20120242. Epub 2012 May 14.
[55] Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2699-704. doi: 10.1073/pnas.0711278105. Epub 2008 Feb 8.
[56] Mouslech Z, Valla V. Endocannabinoid system: An overview of its potential in current medical practice. Neuro Endocrinol Lett. 2009;30(2):153-79.
[57] Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016 Apr 1;79(7):516-25. doi: 10.1016/j.biopsych.2015.07.028. Epub 2015 Oct 30.
[58]. Riebe CJ, Pamplona FA, Kamprath K, Wotjak CT. Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience. 2012 Mar 1;204:159-85. doi: 10.1016/j.neuroscience.2011.11.057. Epub 2011 Dec 3
[59] McLaughlin RJ, Hill MN, Gorzalka BB. A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Neurosci Biobehav Rev. 2014 May;42:116-31. doi: 10.1016/j.neubiorev.2014.02.006. Epub 2014 Feb 26.
[60] Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol. 2008 Jun;13(2):196-212. doi: 10.1111/j.1369-1600.2008.00104.x. Epub 2008 Apr 16.
[61] Alteba S, Korem N, Akirav I. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood. Learn Mem. 2016 Jun 17;23(7):349-58. doi: 10.1101/lm.041608.116. Print 2016 Jul.
[62] Mizrachi Zer-Aviv T, Segev A, Akirav I. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. Behav Pharmacol. 2016 Oct;27(7):561-9. doi: 10.1097/FBP.0000000000000253.
[63] Yarnell S. The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature. Prim Care Companion CNS Disord. 2015 May 7;17(3). doi: 10.4088/PCC.15r01786. eCollection 2015.
[64] Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depress Anxiety. 2017 Mar;34(3):207-216. doi: 10.1002/da.22596. Epub 2017 Feb 28.
[65] Jurkus R, Day HL, Guimarães FS, Lee JL, Bertoglio LJ, Stevenson CW. Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders. Front Pharmacol. 2016 Nov 24;7:454. eCollection 2016.
[66] Abush H1, Akirav I. Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory. Neuropsychopharmacology. 2013 Jul;38(8):1521-34. doi: 10.1038/npp.2013.51. Epub 2013 Feb 20.
[67] Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002 Aug 1;418(6897):530-4.
[68] Papini S, Sullivan GM, Hien DA, Shvil E, Neria Y. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research. Biol Psychol. 2015 Jan;104:8-18. doi: 10.1016/j.biopsycho.2014.10.010. Epub 2014 Nov 4.
[69] Guimarães FS1, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl). 1990;100(4):558-9.
[70] Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther. 1990 Jun;253(3):1002-9.
[71] Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.
[72] Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci Biobehav Rev. 2017 Jan;72:310-324. doi: 10.1016/j.neubiorev.2016.11.012. Epub 2016 Nov 22.
[73] Stanley CP, Hind WH, O'Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013 Feb;75(2):313-22. doi: 10.1111/j.1365-2125.2012.04351.x.
[74] Jadoon KA, Tan GD, O'Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017 Jun 15;2(12). pii: 93760. doi: 10.1172/jci.insight.93760.
[75] Sultan SR, Millar SA, England TJ, O'Sullivan SE. A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol. Front Pharmacol. 2017 Feb 24;8:81. doi: 10.3389/fphar.2017.00081. eCollection 2017.
[76] Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G, Memo M, Bonini SA. Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Horm Mol Biol Clin Investig. 2018 Mar 30. pii: /j/hmbci.ahead-of-print/hmbci-2018-0013/hmbci-2018-0013.xml. doi: 10.1515/hmbci-2018-0013.
[77] Gatta-Cherifi B, Cota D. Endocannabinoids and Metabolic Disorders. Handb Exp Pharmacol. 2015;231:367-91. doi: 10.1007/978-3-319-20825-1_13.
[78] Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M, Motta A, Di Marzo V. Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. J Hepatol. 2015 Jun;62(6):1382-90. doi: 10.1016/j.jhep.2015.01.001. Epub 2015 Jan 13
[79] Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 2016 Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29.
[80] Horváth B, Mukhopadhyay P, Haskó G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012 Feb;180(2):432-42. doi: 10.1016/j.ajpath.2011.11.003. Epub 2011 Dec 5.
[81] Murillo-Rodríguez E, Sarro-Ramírez A, Sánchez D, Mijangos-Moreno S, Tejeda-Padrón A, Poot-Aké A, Guzmán K, Pacheco-Pantoja E, Arias-Carrión O. Potential effects of cannabidiol as a wake-promoting agent. Curr Neuropharmacol. 2014 May;12(3):269-72. doi: 10.2174/1570159X11666131204235805.
[82] Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017 Jun 1;2(1):139-154. doi: 10.1089/can.2016.0034. eCollection 2017.
[83] Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73.
[84] Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713-24. doi: 10.1172/JCI64628. Epub 2014 Jul 25.
[85] Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011 Sep 1;6(4):237-49.
[86] Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011 May;36(6):1219-26. doi: 10.1038/npp.2011.6. Epub 2011 Feb 9.
[87] Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76(3):245-50.
[88] Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993 Jan;7(1 Suppl):82-8. doi: 10.1177/026988119300700112.
[89] Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18(32):4966-79.
[90] Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010 Feb;35(3):764-74. doi: 10.1038/npp.2009.184. Epub 2009 Nov 18.
[91] Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011 Jan;25(1):121-30. doi: 10.1177/0269881110379283. Epub 2010 Sep 9.
[95] Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004 Feb;29(2):417-26.
[96] Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, Curran HV, Morgan CJ. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). 2013 Apr;226(4):781-92. doi: 10.1007/s00213-012-2955-y. Epub 2013 Jan 10.
[97] Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5.
[98] Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008 Apr;192(4):306-7. doi: 10.1192/bjp.bp.107.046649.
[99] Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study. Br J Psychiatry. 2010 Oct;197(4):285-90. doi: 10.1192/bjp.bp.110.077503.
[100] Kendall DA, Yudowski GA. Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Front Cell Neurosci. 2017 Jan 4;10:294. doi: 10.3389/fncel.2016.00294. eCollection 2016.
[101] Malfitano AM, Basu S, Maresz K, Bifulco M, Dittel BN. What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol. 2014 Oct;26(5):369-79. doi: 10.1016/j.smim.2014.04.002. Epub 2014 May 28.
[102] Rodríguez-Muñoz M, Sánchez-Blázquez P, Merlos M, Garzón-Niño J. Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget. 2016 Aug 23;7(34):55840-55862. doi: 10.18632/oncotarget.10095.
[103] Owolabi JO, Olatunji SY, Olanrewaju AJ. Caffeine and Cannabis Effects on Vital Neurotransmitters and Enzymes in the Brain Tissue of Juvenile Experimental Rats. Ann Neurosci. 2017 May;24(2):65-73. doi: 10.1159/000475895. Epub 2017 May 12.
[104] Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3.
[105] Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009 May;23(5):597-602. doi: 10.1002/ptr.2625.
[106] Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009 Oct;30(10):515-27. doi: 10.1016/j.tips.2009.07.006. Epub 2009 Sep 2.
[107] Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x.
[108] Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci. 2008 Dec;122(6):1378-82. doi: 10.1037/a0013278.
[109] Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G. Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210.
[110] Chagas MH, Crippa JA, Zuardi AW, Hallak JE, Machado-de-Sousa JP, Hirotsu C, Maia L, Tufik S, Andersen ML. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013 Mar;27(3):312-6. doi: 10.1177/0269881112474524. Epub 2013 Jan 23.
[111] Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett. 2006 Aug 7;580(18):4337-45. Epub 2006 Jul 10.
[112] Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004 Jun;24(3):305-13.
[113] Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, Winkel G, Sinha R, Jutras-Aswad D, Huestis MA, Hurd YL. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015 May-Jun;9(3):204-10. doi: 10.1097/ADM.0000000000000118.
[114] Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95. doi: 10.3109/03602532.2013.849268. Epub 2013 Oct 25.
[115] Ujváry I, Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1:90–101
[116] Bornheim LM, Everhart ET, Li J, Correia MA. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 1994 Jul 5; 48(1):161-71.
[117] Brzozowska N, Li KM, Wang XS, Booth J, Stuart J, McGregor IS, Arnold JC. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ. 2016; 4():e2081.
[118] Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. Epub 2015 Dec 19.
[119] Schiavon AP, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:27-34. doi: 10.1016/j.pnpbp.2015.06.017. Epub 2015 Jul 14.
[120] Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9.
[121] Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, Crippa JAS. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol. 2017 May 11;8:259. doi: 10.3389/fphar.2017.00259. eCollection 2017.
[122] Peres FF, Levin R, Almeida V, Zuardi AW, Hallak JE, Crippa JA, Abilio VC. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Front Pharmacol. 2016 Sep 9;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016.
[123] Gomes FV, Issy AC, Ferreira FR, Viveros MP, Del Bel EA, Guimarães FS. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol. 2014 Oct 31;18(5). pii: pyu041. doi: 10.1093/ijnp/pyu041.
[124] Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Chagas MH, Hallak JE, Zuardi AW, Quevedo J, Crippa JA. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol. 2011 Feb;25(2):274-80. doi: 10.1177/0269881109106925. Epub 2009 Nov 25
[125] Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009 Nov 25;29(47):14764-9. doi: 10.1523/JNEUROSCI.4291-09.2009.
[126] Prud'homme M, Cata R, Jutras-Aswad D. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Subst Abuse. 2015 May 21;9:33-8. doi: 10.4137/SART.S25081. eCollection 2015.
[127] Kleczkowska P, Smaga I, Filip M, Bujalska-Zadrozny M. Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug? Neurotox Res. 2016 Jan;29(1):173-96. doi: 10.1007/s12640-015-9555-7. Epub 2015 Sep 9.
[128] Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013 Sep;38(9):2433-6. doi: 10.1016/j.addbeh.2013.03.011. Epub 2013 Apr 1.
[129] Viudez-Martínez A, García-Gutiérrez MS, Navarrón CM, Morales-Calero MI, Navarrete F, Torres-Suárez AI, Manzanares J. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol. 2018 Jan;23(1):154-164. doi: 10.1111/adb.12495. Epub 2017 Feb 13.
[130] Sun S, Hu F, Wu J, Zhang S. Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol. 2017 Apr;11:577-585. doi: 10.1016/j.redox.2016.12.029. Epub 2016 Dec 31.
[131] Melser S, Pagano Zottola AC, Serrat R, Puente N, Grandes P, Marsicano G, Hebert-Chatelain E. Functional Analysis of Mitochondrial CB1 Cannabinoid Receptors (mtCB1) in the Brain. Methods Enzymol. 2017;593:143-174. doi: 10.1016/bs.mie.2017.06.023. Epub 2017 Jul 14.
[132] Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med. 2011 Sep 1;51(5):1054-61. doi: 10.1016/j.freeradbiomed.2011.01.007. Epub 2011 Jan 14.
[133] Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JE, Zuardi AW, Crippa JA, Quevedo J. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Rev Bras Psiquiatr. 2013 Oct-Dec;35(4):380-6. doi: 10.1590/1516-4446-2012-0886. Epub 2013 Dec 23.
[134] Zuardi AW, Guimarães FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. 1993 Feb;26(2):213-7.
[135] Appiah-Kusi E, Mondelli V, McGuire P, et al. Effects of cannabidiol treatment on cortisol response to social stress in subjects at high risk of developing psychosis. Psychoneuroendocrinology. 2016;7(Supplement):23–24
[136] Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015 Aug;56(8):1246-51. doi: 10.1111/epi.13060. Epub 2015 Jun 26
[137] Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009 Nov;23(8):979-83. doi: 10.1177/0269881108096519. Epub 2008 Sep 18.
[138] Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012 Mar 20;2:e94. doi: 10.1038/tp.2012.15
[139] Leweke F.M., Koethe D., Pahlisch F., Schreiber D., Gerth C.W., Nolden B.M., Klosterkötter J., Hellmich M., Piomelli D. S39-02 Antipsychotic effects of cannabidiol. Eur. Psychiatry. 2009;24:S207.
[140] Grotenhermen F, Müller-Vahl K. Cannabis und Cannabinoide in der Medizin: Fakten und Ausblick. Suchttherapie. 2016;17:71–76
[141] Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24.
[142] Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol. 2014 Nov;28(11):1088-98. doi: 10.1177/0269881114550355. Epub 2014 Sep 18.
[143] Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991 Nov;40(3):701-8.
[144] Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, Israeli M, Levy-Assaraf M, Gruenewald T, Mechoulam R, Raanani P, Ram R. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5. doi: 10.1016/j.bbmt.2015.05.018. Epub 2015 May 30.
[145]. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des. 2012;18(32):5131-40
[146] Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002 May 14;58(9):1404-7.
[147] Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517-26.
[148] Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006 Nov;17(6):636-41. Epub 2006 Mar 22.
[149] Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003 Feb;17(1):21-9.
[150] Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004 Aug;10(4):425-33.
[151] Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.
[152] Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. J Clin Psychiatry. 2016 Aug;77(8):1050-64. doi: 10.4088/JCP.15r10036.
[153] Lim K, See YM, Lee J. A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):301-312. doi: 10.9758/cpn.2017.15.4.301.
[154] Zuardi AW1. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006 Jun;28(2):153-7. Epub 2006 Jun 26.
[155] Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005 Jun;81(2):331-42.
[156] Patel S, Hillard CJ. Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci. 2009;1:347-71. doi: 10.1007/978-3-540-88955-7_14.
[157] Huang WJ, Chen WW, Zhang X. Endocannabinoid system: Role in depression, reward and pain control (Review). Mol Med Rep. 2016 Oct;14(4):2899-903. doi: 10.3892/mmr.2016.5585. Epub 2016 Aug 1.
[158] Riebe CJ, Wotjak CT. Endocannabinoids and stress. Stress. 2011 Jul;14(4):384-97. doi: 10.3109/10253890.2011.586753.
[159] Witkamp RF. The role of fatty acids and their endocannabinoid-like derivatives in the molecular regulation of appetite. Mol Aspects Med. 2018 Jan 19. pii: S0098-2997(17)30142-5. doi: 10.1016/j.mam.2018.01.002.
[160] Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Fatty Acid modulation of the endocannabinoid system and the effect on food intake and metabolism. Int J Endocrinol. 2013;2013:361895. doi: 10.1155/2013/361895. Epub 2013 May 26.
[161] Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2017 Jul 7:1-20. doi: 10.1080/1028415X.2017.1347373.
[162] Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018 Jan;43(1):155-172. doi: 10.1038/npp.2017.130. Epub 2017 Jun 27.
[163] Lahesmaa M, Eriksson O, Gnad T, Oikonen V, Bucci M, Hirvonen J, Koskensalo K, Teuho J, Niemi T, Taittonen M, Lahdenpohja S, Din MU, Haaparanta-Solin M, Pfeifer A, Virtanen KA, Nuutila P. Cannabinoid Type 1 Receptors are Upregulated During Acute Activation of Brown Adipose Tissue. Diabetes. 2018 Apr 12. pii: db171366. doi: 10.2337/db17-1366.
[164] Busquets-Garcia A, Gomis-González M, Srivastava RK, Cutando L, Ortega-Alvaro A, Ruehle S, Remmers F, Bindila L, Bellocchio L, Marsicano G, Lutz B, Maldonado R, Ozaita A. Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation. Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9904-9. doi: 10.1073/pnas.1525066113. Epub 2016 Aug 15.
[165] Uhernik AL, Montoya ZT, Balkissoon CD, Smith JP. Learning and memory is modulated by cannabidiol when administered during trace fear-conditioning. Neurobiol Learn Mem. 2018 Mar;149:68-76. doi: 10.1016/j.nlm.2018.02.009. Epub 2018 Feb 9.
[166] Wright MJ Jr, Vandewater SA, Taffe MA. Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol. J Pharmacol. 2013 Dec;170(7):1365-73. doi: 10.1111/bph.12199.
[167] Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol. 2010 Jun;160(3):523-9. doi: 10.1111/j.1476-5381.2010.00745.x.
[168] Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, Matias I, De Smedt-Peyrusse V, Labrousse VF, Bretillon L, Matute C, Rodríguez-Puertas R, Layé S, Manzoni OJ.Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci. 2011 Mar;14(3):345-50. doi: 10.1038/nn.2736. Epub 2011 Jan 30.
[169] Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9099-104. doi: 10.1073/pnas.0803601105. Epub 2008 Jun 23.
[170] Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia. 2004 May;59(5):440-52.
[171] Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and Pain: A Clinical Review. Cannabis Cannabinoid Res. 2017 May 1;2(1):96-104. doi: 10.1089/can.2017.0017. eCollection 2017.
[172] Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Curr Rheumatol Rep. 2017 Oct 5;19(11):67. doi: 10.1007/s11926-017-0693-1.
[173] Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-73. doi: 10.1001/jama.2015.6358.
[174] Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014 Jun 5;370(23):2219-27. doi: 10.1056/NEJMra1402309.
[175] Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, Lançon C. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20(25):4112-8.
[176] Bolla KI, Lesage SR, Gamaldo CE, Neubauer DN, Funderburk FR, Cadet JL, David PM, Verdejo-Garcia A, Benbrook AR. Sleep disturbance in heavy marijuana users. Sleep. 2008 Jun;31(6):901-8.
[177] Feinberg I, Jones R, Walker J, Cavness C, Floyd T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther. 1976 Jun;19(6):782-94.
[178] Eisenstein TK, Meissler JJ. Effects of Cannabinoids on T-cell Function and Resistance to Infection. J Neuroimmune Pharmacol. 2015 Jun;10(2):204-16. doi: 10.1007/s11481-015-9603-3. Epub 2015 Apr 16.
[179] National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12.
[180] Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 2014 Oct;39(5):564-6. doi: 10.1111/jcpt.12179. Epub 2014 May 21.
[181] Khoury JM, Neves MCLD, Roque MAV, Queiroz DAB, Corrêa de Freitas AA, de Fátima Â, Moreira FA, Garcia FD. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry. 2017 Feb 20:1-16. doi: 10.1080/15622975.2017.1285049.
[182] Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport. 2003 Dec 2;14(17):2209-11.
[183] Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9406-11. doi: 10.1073/pnas.0914661107. Epub 2010 May 3.
[184] de Oliveira Alvares L, Engelke DS, Diehl F, Scheffer-Teixeira R, Haubrich J, de Freitas Cassini L, Molina VA, Quillfeldt JA. Stress response recruits the hippocampal endocannabinoid system for the modulation of fear memory. Learn Mem. 2010 Mar 26;17(4):202-9. doi: 10.1101/lm.1721010. Print 2010 Apr.
[185] di Tomaso E, Beltramo M, Piomelli D. Brain cannabinoids in chocolate. Nature. 1996 Aug 22;382(6593):677-8.
[186] Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007 Jan;13(1):35-7. Epub 2006 Dec 10.
[187] Korte G, Dreiseitel A, Schreier P, Oehme A, Locher S, Geiger S, Heilmann J, Sand PG. Tea catechins' affinity for human cannabinoid receptors. Phytomedicine. 2010 Jan;17(1):19-22. doi: 10.1016/j.phymed.2009.10.001. Epub 2009 Nov 7.
[188] Cornelis MC, Erlund I, Michelotti GA, Herder C, Westerhuis JA, Tuomilehto J. Metabolomic response to coffee consumption: application to a three-stage clinical trial. J Intern Med. 2018 Feb 12. doi: 10.1111/joim.12737.
[189] Rossi S, De Chiara V, Musella A, Mataluni G, Sacchetti L, Siracusano A, Bernardi G, Usiello A, Centonze D. Caffeine drinking potentiates cannabinoid transmission in the striatum: interaction with stress effects. Neuropharmacology. 2009 Mar;56(3):590-7. doi: 10.1016/j.neuropharm.2008.10.013. Epub 2008 Nov 8.
[190] Lu AT, Ogdie MN, Järvelin MR, Moilanen IK, Loo SK, McCracken JT, McGough JJ, Yang MH, Peltonen L, Nelson SF, Cantor RM, Smalley SL. Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1488-94. doi: 10.1002/ajmg.b.30693.
[191] Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001 Feb;15(2):300-2. Epub 2000 Dec 8.
[192] Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004 Apr;65(4):999-1007.
[193] Hill MN, Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord. 2013 Oct 22;3(1):19. doi: 10.1186/2045-5380-3-19.
[194] Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B. The endocannabinoid system as a target for addiction treatment: Trials and tribulations. Neuropharmacology. 2017 Sep 15;124:73-83. doi: 10.1016/j.neuropharm.2017.05.031. Epub 2017 May 28.
[195] Lisboa SF, Gomes FV, Terzian AL, Aguiar DC, Moreira FA, Resstel LB, Guimarães FS. The Endocannabinoid System and Anxiety. Vitam Horm. 2017;103:193-279. doi: 10.1016/bs.vh.2016.09.006. Epub 2016 Nov 2.
[196] D'Addario 1, Di Francesco A, Pucci M, Finazzi Agrò A, Maccarrone M. Epigenetic mechanisms and endocannabinoid signalling. FEBS J. 2013 May;280(9):1905-17. doi: 10.1111/febs.12125. Epub 2013 Feb 11.
[197] Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006 Jun;5(3):272-92.
[198] Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol. 2008 Jun;20(6):850-7. doi: 10.1111/j.1365-2826.2008.01728.x.
[199] Basu S, Ray A, Dittel BN. Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol. 2011 Dec 1;187(11):5720-32. doi: 10.4049/jimmunol.1102195. Epub 2011 Nov 2.
[200] Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2001 Mar 29;356(1407):381-408.
[201] Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol. 2003 Nov;140(5):790-801. Epub 2003 Sep 29.
[202] Murillo-Rodríguez E, Sánchez-Alavez M, Navarro L, Martínez-González D, Drucker-Colín R, Prospéro-García O. Anandamide modulates sleep and memory in rats. Brain Res. 1998 Nov 23;812(1-2):270-4.
[203] Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res. 2011 Apr;50(2):193-211. doi: 10.1016/j.plipres.2011.01.001. Epub 2011 Feb 2.
[204] Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005 May;106(2):133-45. Epub 2005 Jan 11.
[205] Befort K. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol. 2015 Feb 5;6:6. doi: 10.3389/fphar.2015.00006. eCollection 2015.
[206] Niederhoffer N, Hansen HH, Fernandez-Ruiz JJ, Szabo B. Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br J Pharmacol. 2001 Nov;134(6):1319-27.
[207] Scerif M, Füzesi T, Thomas JD, Kola B, Grossman AB, Fekete C, Korbonits M. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. J Endocrinol. 2013 Sep 9;219(1):79-88. doi: 10.1530/JOE-13-0192. Print 2013 Oct.
[208] Aggarwal S, Shavalian B, Kim E, Rawls SM. Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception. Pharmacol Biochem Behav. 2009 Oct;93(4):426-32. doi: 10.1016/j.pbb.2009.06.004. Epub 2009 Jun 16.
[209] Staniaszek LE, Norris LM, Kendall DA, Barrett DA, Chapman V. Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids. Br J Pharmacol. 2010 Jun;160(3):669-76. doi: 10.1111/j.1476-5381.2010.00703.x.
[210] Börner C, Höllt V, Kraus J. Mechanisms of the inhibition of nuclear factor-κB by morphine in neuronal cells. Mol Pharmacol. 2012 Apr;81(4):587-97. doi: 10.1124/mol.111.076620. Epub 2012 Jan 18.
[211] García-Gutiérrez MS1, Manzanares J. The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines. J Psychopharmacol. 2010 May;24(5):757-65. doi: 10.1177/0269881109106910. Epub 2009 Oct 13.
[212] Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med. 2016 Oct 20;26:16071. doi: 10.1038/npjpcrm.2016.71.
[213] Kogan NM, Melamed E, Wasserman E, Raphael B, Breuer A, Stok KS, Sondergaard R, Escudero AV, Baraghithy S, Attar-Namdar M, Friedlander-Barenboim S, Mathavan N, Isaksson H, Mechoulam R, Müller R, Bajayo A, Gabet Y, Bab I. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. J Bone Miner Res. 2015 Oct;30(10):1905-13. doi: 10.1002/jbmr.2513. Epub 2015 May 10.
[214] Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol Res. 2017 May;119:358-370. doi: 10.1016/j.phrs.2017.02.022. Epub 2017 Feb 27.
[215] Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012 Mar 20;2:e94. doi: 10.1038/tp.2012.15.
[216] Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17(14):1468-86.
[217] Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010 Jan;159(1):122-8. doi: 10.1111/j.1476-5381.2009.00521.x. Epub 2009 Dec 4.
[218] Furey SA, Waksman JA, Dash BH. Nonprescription ibuprofen: side effect profile. Pharmacotherapy. 1992;12(5):403-7.
[219] Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23.
[220]. Haj-Dahmane S, Shen RY. Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology. 2011 Sep;61(3):414-20. doi: 10.1016/j.neuropharm.2011.02.016. Epub 2011 Feb 24
[221] Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):417S-427S.
[222] Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. 2017 Oct;174(19):3242-3256. doi: 10.1111/bph.13724. Epub 2017 Mar 9.
[223] Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther. 2009 Winter;15(1):65-75. doi: 10.1111/j.1755-5949.2008.00065.x.
[224] Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martínez-Orgado J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res. 2008 Dec;64(6):653-8. doi: 10.1203/PDR.0b013e318186e5dd.
[225] Hayakawa K, Mishima K, Fujiwara M. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals (Basel). 2010 Jul 8;3(7):2197-2212.
[226] Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1.
[227] Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009 Feb 18;29(7):2053-63. doi: 10.1523/JNEUROSCI.4212-08.2009.
[228] Britch SC, Wiley JL, Yu Z, Clowers BH, Craft RM. Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug Alcohol Depend. 2017 Jun 1;175:187-197. doi: 10.1016/j.drugalcdep.2017.01.046. Epub 2017 Apr 15.
[229] Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008 Feb;4(1):245-59.
[230] Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018 Mar 7;3:CD012182. doi: 10.1002/14651858.CD012182.pub2.
[231] Miller RJ, Miller RE. Is cannabis an effective treatment for joint pain? Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):59-67. Epub 2017 Sep 28
[232] Häuser W1, Fitzcharles MA, Radbruch L, Petzke F. Cannabinoids in Pain Management and Palliative Medicine. Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634. doi: 10.3238/arztebl.2017.0627.
[233] Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010 Aug;35(9):1879-85. doi: 10.1038/npp.2010.58. Epub 2010 Apr 28.
[234] Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol. 2005 Apr;144(8):1032-6.
[235] Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther. 2004 Mar;308(3):838-45. Epub 2003 Nov 14.
[236] Romano B, Borrelli F, Pagano E, Cascio MG, Pertwee RG, Izzo AA. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine. 2014 Apr 15;21(5):631-9. doi: 10.1016/j.phymed.2013.11.006. Epub 2013 Dec 25.
[237] Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma. 2003 Oct;44(10):1767-73.
[238] McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 2006 Sep;70(3):897-908. Epub 2006 Jun 5.
[239] Lukhele ST, Motadi LR. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement Altern Med. 2016 Sep 1;16(1):335. doi: 10.1186/s12906-016-1280-0.
[240] Fraguas-Sánchez AI, Fernández-Carballido A, Torres-Suárez AI. Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. Expert Opin Investig Drugs. 2016 Nov;25(11):1311-1323. Epub 2016 Sep 28.
[241] McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011 Aug;129(1):37-47. doi: 10.1007/s10549-010-1177-4. Epub 2010 Sep 22.
[242] Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011 Jul;10(7):1161-72. doi: 10.1158/1535-7163.MCT-10-1100. Epub 2011 May 12.
[243] Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x.
[244] Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012 Nov;167(6):1218-31. doi: 10.1111/j.1476-5381.2012.02050.x.
[245] Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem Pharmacol. 2014 Nov 15;92(2):312-25. doi: 10.1016/j.bcp.2014.07.014. Epub 2014 Jul 25.
[246] Srivastava MD, Srivastava BI, Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology. 1998 Nov;40(3):179-85.
[247] Formukong EA, Evans AT, Evans FJ. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation. 1988 Aug;12(4):361-71.
[248] Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7.
[249] Zgair A,, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, McArthur JW, Cheng YK, Hennig IM, Barrett DA, Fischer PM, Constantinescu CS, Gershkovich P. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017 Nov 6;7(1):14542. doi: 10.1038/s41598-017-15026-z.
[250] Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol. 2005 Sep;166(1-2):3-18.
[251] Jenny NS. Inflammation in aging: cause, effect, or both? Discov Med. 2012 Jun;13(73):451-60.
[252] Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res. 2013 May;27(5):633-6. doi: 10.1002/ptr.4781. Epub 2012 Jul 20.
[253] De Filippis, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, Sarnelli G, Cuomo R, Steardo L, De Man JG, Iuvone T. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One. 2011;6(12):e28159. doi: 10.1371/journal.pone.0028159. Epub 2011 Dec 6.
[254] Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018 Mar 19;24(4):714-724. doi: 10.1093/ibd/izy002.
[255] Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980 Sep;28(3):409-16.
[256] Sauer MA, Rifka SM, Hawks RL, Cutler GB Jr, Loriaux DL. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther. 1983 Feb;224(2):404-7.
[257] Lee SY, Oh SM, Chung KH. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):270-8. Epub 2006 Feb 24.
[258] Lanz C, Mattsson J, Soydaner U, Brenneisen R. Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PLoS One. 2016 Jan 19;11(1):e0147286. doi: 10.1371/journal.pone.0147286. eCollection 2016.
[259] Varlet V. Drug Vaping: From the Dangers of Misuse to New Therapeutic Devices. Toxics. 2016 Dec 16;4(4). pii: E29. doi: 10.3390/toxics4040029.
[260] Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006 Oct;15(5):349-53.
[261] Mannila J, Järvinen T, Järvinen K, Jarho P. Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci. 2007 Feb;96(2):312-9.
[262] Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.
[263] Ujváry I, Hanuš L. Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy. Cannabis Cannabinoid Res. 2016 Mar 1;1(1):90-101. doi: 10.1089/can.2015.0012. eCollection 2016.
[264] Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, Hennig IM, Barrett DA, Constantinescu CS, Fischer PM, Gershkovich P. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. 2016 Aug 15;8(8):3448-59. eCollection 2016.
[265] Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5.
[266] Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003 Feb;17(1):21-9.
[267] Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004 Dec;112(3):299-306.
[268] Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.
[269] Yamaori S, Kinugasa Y, Jiang R, Takeda S, Yamamoto I, Watanabe K. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Sci. 2015 Sep 1;136:87-93. doi: 10.1016/j.lfs.2015.07.007. Epub 2015 Jul 15.
[270] Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K.Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332-8. Epub 2013 Jan 15.
[271] Zendulka O, DovrtÄlová G, Nosková K, Turjap M, Šulcová A, Hanuš L, JuÅica J. Cannabinoids and Cytochrome P450 Interactions. Curr Drug Metab. 2016;17(3):206-26.
[272] Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997 Jan;30(1):1-5.
[273] Connor KM, Davidson JR. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int Clin Psychopharmacol. 2002 Jul;17(4):185-8.
[274] Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Phytomedicine. 2003 Nov;10(8):631-9.
[275] Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord. 2004 Feb;78(2):101-10.
[276] Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009 Aug;205(3):399-407. doi: 10.1007/s00213-009-1549-9. Epub 2009 May 9.
[277] Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl). 2001 Sep;157(3):277-83.
[278] Lu K, Gray MA, Oliver C, Liley DT, Harrison BJ, Bartholomeusz CF, Phan KL, Nathan PJ. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol. 2004 Oct;19(7):457-65.
[279] Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007 Jan;74(1):39-45. Epub 2006 Aug 22.
[280] Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy ff an ethanolic extract of withania somnifera. Indian J Psychiatry. 2000 Jul;42(3):295-301.
[281] Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255-62. doi: 10.4103/0253-7176.106022.
[282] Hoge EA, Bui E, Marques L, Metcalf CA, Morris LK, Robinaugh DJ, Worthington JJ, Pollack MH, Simon NM. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013 Aug;74(8):786-92. doi: 10.4088/JCP.12m08083.
[283] Chen KW, Berger CC, Manheimer E, Forde D, Magidson J, Dachman L, Lejuez CW. Meditative therapies for reducing anxiety: a systematic review and meta-analysis of randomized controlled trials. Depress Anxiety. 2012 Jul;29(7):545-62. doi: 10.1002/da.21964. Epub 2012 Jun 14.
[284] Agarwal KA, Tripathi CD, Agarwal BB, Saluja S. Efficacy of turmeric (curcumin) in pain and postoperative fatigue after laparoscopic cholecystectomy: a double-blind, randomized placebo-controlled study. Surg Endosc. 2011 Dec;25(12):3805-10. doi: 10.1007/s00464-011-1793-z. Epub 2011 Jun 14.
[285] Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010 Jun;52(2 Suppl 1):55-62.
[286] Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010 Dec;15(4):337-44.
[287] Di Pierro F, Rapacioli G, Di Maio EA, Appendino G, Franceschi F, Togni S. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva(®)), nimesulide, and acetaminophen. J Pain Res. 2013;6:201-5. doi: 10.2147/JPR.S42184. Epub 2013 Mar 8.
[288] Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman AH. Marijuana dependence: not just smoke and mirrors. ILAR J. 2011;52(3):295-308. doi: 10.1093/ilar.52.3.295.
[289] Panlilio LV, Goldberg SR, Justinova Z. Cannabinoid abuse and addiction: Clinical and preclinical findings. Clin Pharmacol Ther. 2015 Jun;97(6):616-27. doi: 10.1002/cpt.118. Epub 2015 May 2.
[290] Piomelli D, Haney M, Budney AJ, Piazza PV. Legal or Illegal, Cannabis Is Still Addictive. Cannabis Cannabinoid Res. 2016 Jan 1;1(1):47-53. doi: 10.1089/can.2015.29004.rtd. eCollection 2016.
[291] Norman RL. Future's Mirror: The Endocannabinoid System in Human Pathology. 2017. CreateSpace Independent Publishing Platform.
[292] Abel, E. Marijuana: The first 12,000 years. 1980. Plenum Press: NY.
[293] Elphick MR1, Egertová M. The phylogenetic distribution and evolutionary origins of endocannabinoid signalling. Handb Exp Pharmacol. 2005;(168):283-97.
[294] Elphick MR. The evolution and comparative neurobiology of endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3201-15. doi: 10.1098/rstb.2011.0394.
[295] Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high-potency Cannabis sativa. J Nat Prod. 2009 ;72(5):906-11. doi: 10.1021/np900067k.
[296] Andre, CM., Hausman, JF, Guerriero, G. Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers in Plant Science, 2016 7, 19. doi.org/10.3389/fpls.2016.00019.
[297] Russo, EB, Jiang, HE, Li, X, Sutton, A, Carboni, A, del Bianco, F, Li, CS. Phytochemical and genetic analyses of ancient cannabis from Central Asia. Journal of Experimental Botany, 59(15), 2008, 4171–4182.
[298] Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-46. Epub 2005 Oct 4.
[299] Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009 Oct;1(7):1333-49. doi: 10.4155/fmc.09.93.
[300] Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clin Pharmacol Ther. 1984 Jan;35(1):26-32.
[301] Gallily R, Hanus L. Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology & Pharmacy 06(02):75-85 2015.
[302] Campbell CT, Phillips MS, Manasco K. Cannabinoids in Pediatrics. J Pediatr Pharmacol Ther. 2017 May-Jun;22(3):176-185. doi: 10.5863/1551-6776-22.3.176.
[303] Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, Fasano A, Bradstreet JJ, Maione S, Antonucci N. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord. 2013 Nov;43(11):2686-95. doi: 10.1007/s10803-013-1824-9.
[304]. Zamberletti E, Gabaglio M, Parolaro D. The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. Int J Mol Sci. 2017 Sep 7;18(9). pii: E1916. doi: 10.3390/ijms18091916.
[305] Hadland SE, Knight JR, Harris SK. Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. J Dev Behav Pediatr. 2015 Feb-Mar;36(2):115-23. doi: 10.1097/DBP.0000000000000129.
[306] Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Epub 2011 Mar 9.
[307] Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, Schleinzer W, Ueberall M, Konrad C. Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. Anesthesiol Res Pract. 2009;2009. pii: 827290. doi: 10.1155/2009/827290. Epub 2009 Oct 25.
[308] Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975 Feb-Mar;15(2-3):139-43.
[309] de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H; Pain and Nociception Neuroscience Research Group. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1079-1086.e4. doi: 10.1016/j.cgh.2016.09.147. Epub 2016 Oct 5.
[310] Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003 Nov;106(1-2):169-72.
[311] Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003 Sep;105(1-2):79-88.
[312] de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. Br J Clin Pharmacol. 2016 Mar;81(3):525-37. doi: 10.1111/bcp.12811. Epub 2016 Jan 17.
[313] Rudroff T, Honce JM. Cannabis and Multiple Sclerosis-The Way Forward. Front Neurol. 2017 Jun 23;8:299. doi: 10.3389/fneur.2017.00299. eCollection 2017
[314] Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517-26.
[315] Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Cano MG2, McManus D, Mallik S, Hobart J; CUPID investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013 Sep;12(9):857-865. doi: 10.1016/S1474-4422(13)70159-5. Epub 2013 Jul 13.
[316] Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K, Nabar N, Cai J. The potential therapeutic effects of THC on Alzheimer's disease. J Alzheimers Dis. 2014;42(3):973-84. doi: 10.3233/JAD-140093.
[317] Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009 Oct;6(4):713-37. doi: 10.1016/j.nurt.2009.08.002.
[318] Sido JM, Jackson AR, Nagarkatti PS, Nagarkatti M. Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. J Mol Med (Berl). 2016 Sep;94(9):1039-51. doi: 10.1007/s00109-016-1404-5. Epub 2016 Apr 1.
[319] Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs. 2003 Jan;12(1):39-49
[320] Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol. 2014 Mar 5;5:37. doi: 10.3389/fphar.2014.00037. eCollection 2014.
[321] Eubanks LM1, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, Dickerson TJ, Janda KD. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm. 2006 Nov-Dec;3(6):773-7.
[322] Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA. 2015 Jun 23-30;313(24):2474-83. doi: 10.1001/jama.2015.6199.
[323] Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008 Jul;109(1):101-10. doi: 10.1097/ALN.0b013e31817881e1.
[324] Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007 Nov;107(5):785-96.
[325] Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014 Oct;174(10):1668-73. doi: 10.1001/jamainternmed.2014.4005.
[326] Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016 Nov;30(11):3682-3689. Epub 2016 Jul 19.
[327] Ahmed W, Katz S. Therapeutic Use of Cannabis in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016 Nov;12(11):668-679.
[328] Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018 Mar;15(3):151-166. doi: 10.1038/nrcardio.2017.130. Epub 2017 Sep 14.
[329] Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002 Nov;42(11 Suppl):64S-70S.
[330] Mendizábal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23.
[331] Waldman M, Hochhauser E, Fishbein M, Aravot D, Shainberg A, Sarne Y. An ultra-low dose of tetrahydrocannabinol provides cardioprotection. Biochem Pharmacol. 2013 Jun 1;85(11):1626-33. doi: 10.1016/j.bcp.2013.03.014. Epub 2013 Mar 26.
[332] Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017 Jul;9(7):2079-2092. doi: 10.21037/jtd.2017.06.104.
[333] Takeda S, Jiang R, Aramaki H, Imoto M, Toda A, Eyanagi R, Amamoto T, Yamamoto I, Watanabe K. Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors. J Pharm Sci. 2011 Mar;100(3):1206-11. doi: 10.1002/jps.22354. Epub 2010 Oct 1.
[334] Fowler CJ. Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. Clin Pharmacol Ther. 2015 Jun;97(6):587-96. doi: 10.1002/cpt.84. Epub 2015 May 2.
[335] Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21.
[336] Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Curr Oncol. 2016 Mar;23(2):S23-32. doi: 10.3747/co.23.3080. Epub 2016 Mar 16.
[337] ÅledziÅski P, Zeyland J, SÅomski R, Nowak A. The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. 2018 Mar;7(3):765-775. doi: 10.1002/cam4.1312. Epub 2018 Feb 23.
[338] Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O'Hearn S. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. 2017 Dec;6(Suppl 2):S215-S222. doi: 10.21037/apm.2017.08.05. Epub 2017 Aug 23.
[339] Martínez-Martínez E, Martín-Ruiz A, Martín P, Calvo V, Provencio M, García JM. CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway. Oncotarget. 2016 Oct 18;7(42):68781-68791. doi: 10.18632/oncotarget.11968.
[340] Kampa-Schittenhelm KM, Salitzky O, Akmut F, Illing B, Kanz L, Salih HR, Schittenhelm MM. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BMC Cancer. 2016 Jan 16;16:25. doi: 10.1186/s12885-015-2029-8.
[341] Kalenderoglou N, Macpherson T, Wright KL Cannabidiol Reduces Leukemic Cell Size - But Is It Important? Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
[342] Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998 Jul 17;353(1):23-31.
[343] Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis Cannabinoid Res. 2016 Jan 1;1(1):44-46. doi: 10.1089/can.2015.29003.ebr. eCollection 2016.
[344] Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344-64. doi: 10.1111/j.1476-5381.2011.01238.x.
[345] Shmist YA, Goncharov I, Eichler M, Shneyvays V, Isaac A, Vogel Z, Shainberg A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem. 2006 Feb;283(1-2):75-83.
[346] Shmist YA, Goncharov I, Eichler M, Shneyvays V, Isaac A, Vogel Z, Shainberg A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem. 2006 Feb;283(1-2):75-83.
[347] Zani A, Braida D, Capurro V, Sala M. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol. 2007 Dec;152(8):1301-11. Epub 2007 Oct 29.
[348] Steffens S1, Pacher P. Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol. 2012 Sep;167(2):313-23. doi: 10.1111/j.1476-5381.2012.02042.x.
[349] Carroll CB1, Zeissler ML, Hanemann CO, Zajicek JP. Δâ¹-tetrahydrocannabinol (Δâ¹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x
[350] Booth JK, Page JE, Bohlmann J. Terpene synthases from Cannabis sativa. PLoS One. 2017 Mar 29;12(3):e0173911. doi: 10.1371/journal.pone.0173911. eCollection 2017.
[351] Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutiérrez S, Martín-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch J, Chaouloff F, López-Rodríguez ML, Grandes P, Rossignol R, Marsicano G. Mitochondrial CBâ receptors regulate neuronal energy metabolism. Nat Neurosci. 2012 Mar 4;15(4):558-64. doi: 10.1038/nn.3053.
[352] Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3326-41. doi: 10.1098/rstb.2011.0388.
[353] Ma L, Jia J, Niu W, Jiang T, Zhai Q, Yang L, Bai F, Wang Q, Xiong L. Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on neurons and mitochondrial functions. Sci Rep. 2015 Jul 28;5:12440. doi: 10.1038/srep12440.
[354] Singh N, Hroudová J, Fišar Z. Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J Mol Neurosci. 2015 Aug;56(4):926-931. doi: 10.1007/s12031-015-0545-2. Epub 2015 Mar 29.
[355] Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 1986 Feb;13(2):77-83.
[356] Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986 Mar;38(1):21-43.
[357] Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec. 1971 Sep;8(4):391-402.
[358] Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007 Aug;4(8):1770-804.
[359] Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992 Sep-Oct;16(5):276-82.
[360] Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma levels of delta 9-tetrahydrocannabinol after intravenous, oral, and smoke administration. NIDA Res Monogr. 1981 Feb;34:250-6.
[361] Law B, Mason PA, Moffat AC, Gleadle RI, King LJ. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol. 1984 May;36(5):289-94.
[362] Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol. 2004 Mar;56(3):291-7.
[363] Morales P, Reggio PH. An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis Cannabinoid Res. 2017 Oct 1;2(1):265-273. doi: 10.1089/can.2017.0036. eCollection 2017.
[364] Gachet MS, Schubert A, Calarco S, Boccard J, Gertsch J. Targeted metabolomics shows plasticity in the evolution of signaling lipids and uncovers old and new endocannabinoids in the plant kingdom. Sci Rep. 2017 Jan 25;7:41177. doi: 10.1038/srep41177.
[365] McPartland JM, Pruitt, P. Sourcing the Code: Searching for the Evolutionary Origins of Cannabinoid Receptors, Vanilloid Receptors, and Anandamide. 2002.
[366] Russo EB, Marcu J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Adv Pharmacol. 2017;80:67-134. doi: 10.1016/bs.apha.2017.03.004. Epub 2017 Jun 5.